Featured Articles

  1. Implications Of California's AB 824 Patent Settlement Regulation 5/21/2025

    California's AB 824 law has important implications for branded and generics companies involved in settlement agreements. AB 824 presumes, for example, that "reverse payment" agreements are illegal.

  2. Reactive To Proactive: A Major Shift In The Fight Against Alzheimer's 5/19/2025

    Improvements in diagnostics for the early detection of Alzheimer's disease have the potential to transform patient care and new drug development, writes Mike Banville, CEO and President at ALZpath.

  3. Innovative Strategies In Early Commercialization: A Leader's Perspective 5/16/2025

    For small pharmas and biotechs approaching a commercial launch, agility and execution are more valuable than waiting for a perfect plan, writes Melinta Therapeutics CEO John Harlow.

  4. Promoting A Newly Approved Indication Against Established Competitors 5/14/2025

    In a follow up to his recent appearance on the Business of Biotech, Tolga Tanguler explains how Alnylam is positioning Amvuttra's new ATTR-CM indication approval against competitors in the category.

  5. The Potential Impact Of U.S. Tariffs On The Biotech Sector: Manufacturing, Funding, And Clinical Trials 5/12/2025

    Syner-G Biopharma Group's Raymond Forslund, Ph.D., MBA explores how U.S. tariffs might affect biotech manufacturing, funding, and clinical research.

  6. Navigating The GLP-1 Litigation Landscape 5/8/2025

    Attorney James Gourley details the many legal issues surrounding the GLP-1 drug market and offers advice to companies on how to anticipate and prepare for new IP, legal, and regulatory developments.

  7. The Convergence Of Consumer Wellness And Healthcare 5/6/2025

    The rise in use of GLP-1 medications is driving a convergence between pharmaceutical therapies and consumer health and wellness offerings, including real-world data collection and behavior management.

  8. Planning For Perseverance 5/2/2025

    AC Immune SA cofounder and CEO Andrea Pfeifer offers lessons in strategy and resilience for building and maintaining a drug development company amid internal and external ups and downs.

  9. Building Uniquity Bio: Teams, Capital, And Strategy 4/30/2025

    Brian Lortie, president and CEO at Uniquity Bio, offered up key insights on building teams, securing capital, and operating with efficiency during a recent Business of Biotech podcast recording.

  10. A Better Way For BD And Commercial Teams To Evaluate Strategic Assets 4/30/2025

    To unlock value and avoid costly mistakes, life sciences BD teams must work with commercial teams to help evaluate potential deals, before key assumptions are locked in, writes Ardelyx's Shetal Vyas.